Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.
about
The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses.Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studiesNeuroprotective activities of CEP-1347 in models of neuroAIDS.STAT3 and its phosphorylation are involved in HIV-1 Tat-induced transactivation of glial fibrillary acidic proteinGenetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research.Inhibition of highly productive HIV-1 infection in T cells, primary human macrophages, microglia, and astrocytes by Sargassum fusiforme.Microglia in human immunodeficiency virus-associated neurodegeneration.Controversies in HIV-associated neurocognitive disordersCerebrospinal fluid is an efficient route for establishing brain infection with feline immunodeficiency virus and transfering infectious virus to the periphery.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.HIV-1 infection and AIDS: consequences for the central nervous system.HIV's double strike at the brain: neuronal toxicity and compromised neurogenesis.Antiretroviral therapy and central nervous system HIV type 1 infectionGlobal gray and white matter metabolic changes after simian immunodeficiency virus infection in CD8-depleted rhesus macaques: proton MRS imaging at 3 T.Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration?Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment.Neuronal Stress and Injury Caused by HIV-1, cART and Drug Abuse: Converging Contributions to HAND.How much do antiretroviral drugs penetrate into the central nervous system?Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia.Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.Raltegravir resistance in the cerebrospinal fluid.Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment.
P2860
Q25257032-84CAA66E-532A-46DC-970C-9C40BB4D5C2CQ28751900-18F8D277-DA63-4A2D-9285-017B9FE75C5DQ33587971-8AD9C993-6483-490E-BC54-40B4FB02A168Q33675464-551AF162-BE47-421F-8DF8-EE924AF92240Q33716348-B6591345-E704-4BC1-B4BD-AD95627F9F28Q34080236-C19C7FAB-0ECC-443F-9931-5DC7B3758C64Q34691336-77A3F627-B7CB-4372-A630-AC209A09A7A6Q34963796-135E1C3C-ACC1-41CF-91DC-76725BB76EFBQ35037015-AB09BB38-3ECB-478A-B381-DC51F6C8307CQ35195923-C8FCB53E-B1AC-4C73-9913-80D6825076FAQ35742512-8F87E693-CBF2-4923-BC89-B2B18FF7C6F8Q36098879-C42231D2-5B83-4074-826C-1FCC214A0836Q36203732-0C9C9E18-6ABD-4A48-8AA4-DFBE21EC5200Q37066982-AEB8D2D1-955E-4C3B-ACD9-422D2DC8F6D1Q37201040-E9FF60F0-85A3-439F-AFEE-045E32C46F17Q37362071-912C613B-C2CC-4E86-AD97-79D7FA3B8D0FQ37436136-89D54185-93E5-495F-966D-54E7C2414CDDQ37492836-170E86CC-D060-45E5-84AD-BB9E91B2A4D1Q37721505-C04AF2F0-DF6A-4CB9-905C-B4CC46F168B0Q38003612-0EBACFC7-6F5E-4C05-BEAA-E53F04324645Q40668682-5BC16046-BAAF-4F49-BE09-3A244F491A44Q41688961-797027B5-9D21-4D5D-9BBA-7F7D02438327Q43470111-00E81C5E-A436-422D-91A9-A1D6AB3F6470Q43871660-859FC1ED-86F5-4750-898C-CC7115EEAA41Q46450181-2D550BE8-1406-48AD-B352-E44BE01A7542Q48889959-1E052A3B-1CD4-4A60-BEF7-91BFC691C830Q49711913-4EB028F4-AEE2-4011-A76D-424DE92B0580Q52627559-9E9A09A7-3B87-4061-856B-3D60515D401FQ55432495-037B21D3-9A05-4416-A127-B455006B7385
P2860
Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Evidence for independent devel ...... rs in the cerebrospinal fluid.
@en
Evidence for independent devel ...... rs in the cerebrospinal fluid.
@nl
type
label
Evidence for independent devel ...... rs in the cerebrospinal fluid.
@en
Evidence for independent devel ...... rs in the cerebrospinal fluid.
@nl
prefLabel
Evidence for independent devel ...... rs in the cerebrospinal fluid.
@en
Evidence for independent devel ...... rs in the cerebrospinal fluid.
@nl
P2093
P1433
P1476
Evidence for independent devel ...... ors in the cerebrospinal fluid
@en
P2093
P304
P356
10.1097/00002030-200009080-00010
P407
P50
P577
2000-09-01T00:00:00Z